The Economist @TheEconomist
“We’ve witnessed promising therapies not reaching patients for non-medical reasons.” Claire Booth of @UCLchildhealth explains why ensuring the widespread access to genome editing therapies must be a priority, on “Babbage” https://t.co/fkWWGMoLYc — PolitiTweet.org